Ta1722, an anti-angiogenesis inhibitor targeted on VEGFR-2 against human hepatoma - 09/10/12
Corresponding author. Tel.: +86 29 82655451; fax: +86 29 8265 5451.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
In order to investigate the anti-angiogenesis potential and related mechanisms of Ta1722 (a novel taspine derivative compound), a series of experiments in vivo and in vitro were carried out. The proliferation on human cell lines of SMMC-7721, A549, MCF-7, Lovo, and ECV304 was examined by MTT. Angiogenesis inhibition was examined by chick embryo chorioallantoic membrane (CAM) angiogenesis and tube formation assays. Related angiogenesis proteins and their mRNA expression were determined by western blotting and RT-PCR. In addition, the SMMC-7721 nude mouse xenotransplant model was used to evaluate the inhibition of tumor growth. The results showed that Ta1722 inhibited cell proliferation, angiogenesis of CAM and tube formation, and downregulated related positive angiogenesis proteins. The above indicated Ta1722 could serve as a promising candidate of angiogenesis inhibitors by interrupting the VEGF/VEGFR-2 pathway.
Le texte complet de cet article est disponible en PDF.Keywords : Angiogenesis, Ta1722, VEGFR-2, Hepatoma
Plan
Vol 66 - N° 7
P. 499-505 - octobre 2012 Retour au numéro
Article précédent
- Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice
- Cristina Maria de Souza, Luciana Fonseca de Carvalho, Tamara da Silva Vieira, Ana Cândida Araújo e Silva, Miriam Teresa Paz Lopes, Mônica Alves Neves Diniz Ferreira, Silvia Passos Andrade, Geovanni Dantas Cassali
- Differential oncogene-related gene expressions in myeloma cells resistant to prednisone and vincristine
- Pelin Mutlu, Ali Ugur Ural, Ufuk Gündüz
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?